While the use of serotonin receptor ligands and TRP channel ligands as anti-inflammatories in the epithelium of the intestines for IBD prevention is still in the experimental stages, the early findings are promising, but there are many limitations to our study and the use of 5-HT2A and TRP channel ligands for the treatment of IBD. Here, HTR2A is linked to inflammatory bowel disease.